Print

Cancer Research Consortium of West Michigan

Adolescent and Young Adult Clinical Trials

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.

Provided drugs are underlined

For more information, call the CRCWM Main office at 616.391.1230 or 800.336.5079

Brain/CNS

Cancer Type: Medulloblastoma
Research Base: COG
Protocol: COG ACNS1442

COG-ACNS1422: A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

Age - Patients must be greater than or equal to 3 years and less than 22 years at the time of planned enrollment on ACNS1422.

Cancer Type: Newly Diagnosed Ependymoma
Research Base: COG
Protocol: COG ACNS0831

COG ACNS0831: Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years. Patients > 12 months and < 21 years of age.

Cancer Type: Neuroblastoma-Biology
Research Base: COG
Protocol: COG ANBL00B1

COG ANBL00B1: Neuroblastoma Classification Biology Studies. All newly diagnosed patients with suspected neuroblastoma, suspected ganglioneuroblastoma, or suspected ganglioneuroma/maturing subtype seen at COG institutions are eligible for this study. 

Cancer Control

Cancer Type: Multi-site Cancer Control
Research Base: COG
Protocol: COG ALTE03N1

COG ALTE03N1: Key Adverse Events after Childhood Cancer. Diagnosis of primary cancer at age 21 or younger, irrespective of current age.

Genitourinary

Cancer Type: Renal-Biology
Research Base: COG
Protocol: COG AREN03B2

COG AREN03B2: Renal Tumors Classification, Biology, and Banking Study. Patients must be < 30 years old at the time of diagnosis.

Germ Cell

Cancer Type: Germ Cell
Research Base: COG
Protocol: COG AGCT1531

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

Age:

  1. Low Risk Stratum (Stage I Ovarian Immature Teratoma and Stage I Malignant GCT (all sites))
    Patients must be < 50 years of age at enrollment.
  2. Standard Risk 1
    Patient must be < 11 years of age at enrollment.
  3. Standard Risk 2
    Patients must be ≥ 11 and < 25 years of age at enrollment.

Leukemia

Cancer Type: Acute Lymphoblastic Leukemia (ALL)
Research Base: COG
Protocol: COG AALL1521

COG-AALL1521: A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway–Mutant Acute Lymphoblastic Leukemia - Temporarily closed

Age ≥ 1 year and ≤ 21 years at time of leukemia diagnosis.

Cancer Type: Relapsed Refractory CD22 B-ALL
Research Base: COG
Protocol: COG AALL1621

COG-AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND# 133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) Temporarily Closed to Accrual

Patients must be ≥1 year and < 22 years of age at the time of enrollment.

Cancer Type: B-ALL Relapse
Research Base: COG
Protocol: COG AALL1331

COG AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Age - Patients ≥1 year and < 31 years of age at the time of relapse will be eligible.

Cancer Type: Acute Promyelocytic Leukemia (APL)
Research Base: COG
Protocol: COG AAML1331
COG AAML1331: A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic
Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid - TEMPORARY CLOSURE (Stratum 1)
 
Patient must be ≥ 12 months and < 22 years of age at first diagnosis of APL
Cancer Type: T-ALL & T-LLy
Research Base: COG
Protocol: COG AALL1231

COG AALL1231: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy). All patients must be > 1 and < 31 years of age. TEMPORARY CLOSURE

Cancer Type: High Risk B-ALL
Research Base: COG
Protocol: COG AALL1131

COG AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations - PARTIAL CLOSURE

Patients must be > 365 days and < 31 years of age



 

Lymphoma

Cancer Type: T-ALL & T-LLy
Research Base: COG
Protocol: COG AALL1231

COG AALL1231: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy). All patients must be > 1 and < 31 years of age. TEMPORARY CLOSURE

Cancer Type: ALCL
Research Base: COG
Protocol: COG ANHL12P1

COG ANHL12P1: A Randomized Phase 2 study of Brentuximab Vedotin (NSC# 749710) and Crizotinib (NSC# 749005) in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma (ALCL) IND #117117. 

Patient must be < 22 years of age.

Multisite

Cancer Type: Germ Cell
Research Base: COG
Protocol: COG AGCT1531

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

Age:

  1. Low Risk Stratum (Stage I Ovarian Immature Teratoma and Stage I Malignant GCT (all sites))
    Patients must be < 50 years of age at enrollment.
  2. Standard Risk 1
    Patient must be < 11 years of age at enrollment.
  3. Standard Risk 2
    Patients must be ≥ 11 and < 25 years of age at enrollment.
Cancer Type: All patients
Research Base: COG
Protocol: COG APEC14B1

Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study

Subjects must be ≤ 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating NCTN) therapeutic study, for whom there is a higher upper age limit.

Cancer Type: Multi-site Cancer Control
Research Base: COG
Protocol: COG ALTE03N1

COG ALTE03N1: Key Adverse Events after Childhood Cancer. Diagnosis of primary cancer at age 21 or younger, irrespective of current age.

Cancer Type: Multisite Long Term Follow-up
Research Base: COG
Protocol: COG ALTE05N1

COG ALTE05N1: Umbrella Long-term Follow-up Protocol. Only available to patients already enrolled on a COG intervention protocol.

Neuroblastoma

Cancer Type: Neuroblastoma-Biology
Research Base: COG
Protocol: COG ANBL00B1

COG ANBL00B1: Neuroblastoma Classification Biology Studies. All newly diagnosed patients with suspected neuroblastoma, suspected ganglioneuroblastoma, or suspected ganglioneuroma/maturing subtype seen at COG institutions are eligible for this study. 

Sarcoma

Cancer Type: Ewing Sarcoma
Research Base: COG
Protocol: COG AEWS1221

COG-AEWS1221: Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma 

Patients ≤ 50 years of age at enrollment will be eligible for this study.

Cancer Type: Soft Tissue Sarcomas
Research Base: COG
Protocol: COG ARST1321

COG ARST1321: Pazopanib Neoadjuvant Trial In Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613) - TEMPORARY CLOSURE

Patients must be ≥ 2 years at the time of the biopsy that established the diagnosis of NRSTS will be eligible

Cancer Type: IR Rhabdomyosarcoma
Research Base: COG
Protocol: COG ARST1431

COG-ARST1431: A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS) - TEMPORARY CLOSURE

Feasibility Phase: Patients must be < 21 years of age at the time of enrollment.
Efficacy Phase: Patients must be ≤ 40 years of age at the time of enrollment.